Shopping Cart

Your shopping cart is currently empty

Polygalacic acid

Name: Polygalacic acid
Brand: TargetMol
SKU: T3767
Price: 89 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T3767Cas No. 22338-71-2

Alias Virgaureagenin G

Polygalacic acid (Virgaureagenin G) is a triterpenoid isolated from the root of Polygala tenuifolia Willd that inhibits MMP expression. Polygalacic acid (Virgaureagenin G) can significantly improve the responsiveness of the cholinergic system, such as decreased acetylcholinesterase (AChE) activity, increased choline acetyltransferase (ChAT) activity, and increased acetylcholine (ACh) levels in the hippocampus and frontal cortex. Polygalacic acid (Virgaureagenin G) can also inhibit IL-1β-induced Wnt/β-catenin activation and mitogen-activated protein kinase (MAPK) signaling pathways in chondrocytes, and is used in osteoarthritis (OA) related research.

Polygalacic acid

😃Good

Purity: 99.82%

Catalog No. T3767Alias Virgaureagenin GCas No. 22338-71-2

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$89	-	In Stock
5 mg	$218	-	In Stock
10 mg	$319	-	In Stock
25 mg	$542	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.82%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Polygalacic acid (Virgaureagenin G) is a triterpenoid isolated from the root of Polygala tenuifolia Willd that inhibits MMP expression. Polygalacic acid (Virgaureagenin G) can significantly improve the responsiveness of the cholinergic system, such as decreased acetylcholinesterase (AChE) activity, increased choline acetyltransferase (ChAT) activity, and increased acetylcholine (ACh) levels in the hippocampus and frontal cortex. Polygalacic acid (Virgaureagenin G) can also inhibit IL-1β-induced Wnt/β-catenin activation and mitogen-activated protein kinase (MAPK) signaling pathways in chondrocytes, and is used in osteoarthritis (OA) related research.
In vitro	Method: Polygalacic acid (Virgaureagenin G) (1,5,10,20,30,40,50μM) was used to treat BV2 and N2a cells, and Polygalacic acid (Virgaureagenin G) (50μM) was selected to treat Aβ42 (10,30,40μM). Treated BV2 cells and observed cell viability. RESULTS Polygalacic acid (Virgaureagenin G) has no toxicity to BV2 and N2a cells; the conditioned medium pretreated with 50 μM Polygalacic acid (Virgaureagenin G) can significantly increase the viability of N2a cells and significantly reduce the apoptosis of N2a neurons induced by Aβ42. Mortality rate. [2]
In vivo	METHODS: Polygalacic acid (Virgaureagenin G) (3, 6 and 12 mg/kg, oral, 14 days), and intraperitoneal injection of scopolamine (1 mg/kg, 14 days) were used to induce memory impairment. Memory-related behaviors were assessed using the Morris water maze; cholinergic and neuroinflammatory activities were measured in brain tissue; superoxide dismutase activity malondialdehyde and reduced glutathione content in the brain were measured. RESULTS Scopolamine treatment significantly increased escape latency, reduced the number of crossovers, and shortened the time spent in the target quadrant, and Polygalacic acid (Virgaureagenin G) reversed these scopolamine-induced effects; Polygalacic acid (Virgaureagenin G) significantly Improved cholinergic system reactivity, such as reduced acetylcholinesterase (AChE) activity, increased choline acetyltransferase (ChAT) activity, and increased acetylcholine (ACh) levels in the hippocampus and frontal cortex; Polygalacic acid (Virgaureagenin G) also showed Significantly improved neuroinflammation and oxidative stress in mice. [3]
Synonyms	Virgaureagenin G

Chemical Properties

Molecular Weight	504.70
Formula	C₃₀H₄₈O₆
Cas No.	22338-71-2
Smiles	CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@H]2C1)C(O)=O
Relative Density.	1.23 g/cm3 (Predicted)

Storage & Solubility Information

Storage

store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 91.00 mg/mL (180.31 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.9814 mL	9.9069 mL	19.8138 mL	99.0688 mL
5 mM	0.3963 mL	1.9814 mL	3.9628 mL	19.8138 mL
10 mM	0.1981 mL	0.9907 mL	1.9814 mL	9.9069 mL
20 mM	0.0991 mL	0.4953 mL	0.9907 mL	4.9534 mL
50 mM	0.0396 mL	0.1981 mL	0.3963 mL	1.9814 mL
100 mM	0.0198 mL	0.0991 mL	0.1981 mL	0.9907 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc